Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral: Vanier Canada Graduate Scholarships

University of Toronto

$150,000.00

Characterization of mechanisms of medulloblastoma metastasis and identification of targeted therapies to prevent and treat metastasis

EF 2017-18

Résumé
Cancer affecting the brain and spinal cord is the second most common type of cancer in children, accounting for 18% of all pediatric cancers. Medulloblastoma is the most common brain cancer in children and can occur in patients in infancy through to adulthood. The current standard of care includes surgical removal of as much tumour as is safely possible, followed by aggressive radiotherapy and chemotherapy regimens to treat the cancer cells that remain after surgery. These modern treatment strategies date back to the 1990s. With this multimodal treatment strategy, survival rates have plateaued at approximately 70%. Additionally, while current treatments can achieve cures in a significant number of these patients, the effects of surgery, radiation, and chemotherapy on the developing brain lead to intellectual impairment, hearing loss, short stature, hormonal dysfunction, and an increased risk of developing secondary cancers early in life. Together, the lack of improvement in survival rates over the past two decades combined with the significant quality of life impairment caused by treatment side effects in survivors creates an urgency to develop novel targeted therapies for these patients. One key discovery is that the leading cause of death in medulloblastoma patients is the spread of the cancer from the initial site. This study will focus on strategies to identify the key pathways involved in the spread of medulloblastoma. We will use emerging genetic technologies to screen for genetic weaknesses that can be exploited to selectively block the spread of cancer cells. Additionally, we will try to better characterize how cancer cells are able to move from the site of the initial tumour into distant sites in the brain and spinal cord. Finally, we will test targeted therapies in mouse models of medulloblastoma to try to prevent cancer spread within the brain and spine.
Programme
Doctoral: Vanier Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
376556
Name
Juraschka Kyle R
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Characterization of mechanisms of medulloblastoma metastasis and identification of targeted therapies to prevent and treat metastasis
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
In Vivo Crispr Screen; Intrathecal Drug Therapy; Medulloblastoma; Metastasis
Abstract
Cancer affecting the brain and spinal cord is the second most common type of cancer in children, accounting for 18% of all pediatric cancers. Medulloblastoma is the most common brain cancer in children and can occur in patients in infancy through to adulthood. The current standard of care includes surgical removal of as much tumour as is safely possible, followed by aggressive radiotherapy and chemotherapy regimens to treat the cancer cells that remain after surgery. These modern treatment strategies date back to the 1990s. With this multimodal treatment strategy, survival rates have plateaued at approximately 70%. Additionally, while current treatments can achieve cures in a significant number of these patients, the effects of surgery, radiation, and chemotherapy on the developing brain lead to intellectual impairment, hearing loss, short stature, hormonal dysfunction, and an increased risk of developing secondary cancers early in life. Together, the lack of improvement in survival rates over the past two decades combined with the significant quality of life impairment caused by treatment side effects in survivors creates an urgency to develop novel targeted therapies for these patients. One key discovery is that the leading cause of death in medulloblastoma patients is the spread of the cancer from the initial site. This study will focus on strategies to identify the key pathways involved in the spread of medulloblastoma. We will use emerging genetic technologies to screen for genetic weaknesses that can be exploited to selectively block the spread of cancer cells. Additionally, we will try to better characterize how cancer cells are able to move from the site of the initial tumour into distant sites in the brain and spinal cord. Finally, we will test targeted therapies in mouse models of medulloblastoma to try to prevent cancer spread within the brain and spine.
Competitiondate
201711
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Juraschka, Kyle R
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~